TIVC — Tivic Health Systems, Inc.

Tivic Health Systems (TIVC) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q3 2025 revenue was $140,000, up from $126,000 in Q3 2024. However, year-to-date revenue was $302,000, down from $600,000 in the same period last year.
• Cost of Sales: Increased to $291,000 in Q3 2025 from $82,000 in Q3 2024, primarily due to $230,000 in inventory reserves.
• Gross Margin: Excluding inventory reserves, gross margins were 42% in Q3 2025, compared to 35% in Q3 2024.
• Operating Expenses: Increased to $2.3 million in Q3 2025 from $1.5 million in Q3 2024, driven by R&D investments and corporate costs.
• Net Loss: Net loss for Q3 2025 was $2.6 million, compared to $1.4 million in Q3 2024. Year-to-date net loss was $6 million, up from $4.2 million in the prior year.
• Cash Position: Cash and cash equivalents totaled $3.5 million as of September 30, 2025, up from $2 million at the end of 2024.

2. Strategic Updates and Business Highlights

• Tivic is undergoing a transformation from consumer health devices to biologic pharmaceuticals, focusing on the immune system.
• The company has licensed entolimod and entelasta, targeting applications in acute radiation syndrome (ARS) and neutropenia.
• Progress includes successful verification of the entolimod cell line and completion of IND transfers for ARS and advanced cancer.
• Tivic is engaging with military stakeholders and BARDA for potential stockpiling opportunities for entolimod as a countermeasure against radiation exposure.
• The VNS program has shown promising results in optimizing stimulation parameters, potentially leading to new commercial opportunities.

3. Forward Guidance and Outlook

• Tivic anticipates moving directly into Phase II clinical studies for entolimod in neutropenia and lymphocyte exhaustion due to existing safety data.
• The company aims to complete its exit from the consumer health market by year-end and focus resources on advancing its biologics pipeline.
• Management is optimistic about securing additional financing and achieving GMP manufacturing validation for entolimod, which is seen as a critical milestone.

4. Bad News, Challenges, or Points of Concern

• The exit from the consumer device market has led to significant inventory reserves and asset write-offs, indicating challenges in transitioning the business model.
• The contract manufacturer faced financial difficulties, causing delays in production schedules for entolimod.
• Increased operating expenses due to R&D investments may pressure short-term financial performance.
• The decline in year-to-date revenue raises concerns about the effectiveness of the transition strategy and market acceptance of new products.

5. Notable Q&A Insights

• Management emphasized the importance of building relationships with military and government stakeholders for entolimod's potential use.
• There was acknowledgment of unexpected findings in the VNS program that may alter the initial commercial strategy.
• The company reassured investors that it does not expect significant additional costs related to exiting the consumer device business, aiming for a clean transition.

Overall, while Tivic Health is making strides in its transformation and advancing its clinical pipeline, it faces challenges related to its previous business model and operational execution. The focus remains on leveraging its biologics portfolio for future growth.